Retatrutide: Is It Really a New Generation Weight Loss Drug Candidate?
Obesity is one of the health problems that continues to receive attention because it is associated with various metabolic disorders and chronic diseases. The development of therapies based on gastrointestinal hormones has subsequently introduced various new drug candidates, one of which is retatrutide.
Retatrutide, also known as LY3437943, is a peptide based drug candidate developed as a triple agonist with activity at three hormone receptors, namely the glucose dependent insulinotropic polypeptide receptor (GIPR), glucagon like peptide 1 receptor (GLP 1R), and glucagon receptor (GCGR).
Table of Content:
- Structure and Characteristics of Retatrutide
- What Are the Potential Side Effects of Retatrutide?
- How Can Retatrutide Be Analyzed in the Laboratory?
Structure and Characteristics of Retatrutide
Retatrutide is a synthetic peptide designed to activate three receptors simultaneously, namely GIPR, GLP 1R, and GCGR. Because it has activity against these three targets, retatrutide is often referred to as a triple agonist or triple hormone receptor agonist.
This approach differs from GLP-1 agonists, which primarily act through GLP-1R, or dual agonists such as tirzepatide, which act on GIPR and GLP-1R. This compound also targets the glucagon receptor, which is expected to provide additional effects on energy regulation and metabolism.
Read Also:
Why Do Drugs Have Different Expiration Dates and Beyond Use Date?
What Are the Potential Side Effects of Retatrutide?
The mechanism of action of this compound is associated with the activation of three hormonal pathways.
1. GLP 1 receptor activation
Activation of GLP 1R is associated with glucose regulation, stimulation of glucose dependent insulin secretion, delayed gastric emptying, and reduced food intake. These effects are among the foundations for the use of GLP 1 based drugs in the management of obesity and metabolic disorders.
2. GIP receptor activation
GIP is an incretin hormone that plays a role in metabolic regulation and insulin responses. Activation of GIPR in combination with GLP 1R is one of the approaches used in the development of therapies based on dual agonists.
3. Glucagon receptor activation
Activation of GCGR is one of the characteristics that most clearly distinguishes this compound. The glucagon pathway is associated with increased energy expenditure and changes in energy substrate utilization.
Theoretically, combining GIPR, GLP 1R, and GCGR activity may provide broader effects on energy balance.
How Can Retatrutide Be Analyzed in the Laboratory?
Laboratory analysis of this compound is important for confirming the identity, content, purity, and characteristics of the tested material. As a peptide molecule with a relatively complex structure, the selection of an analytical method should be adjusted according to the testing objectives and sample characteristics.
One method that can be used is reverse phase high performance liquid chromatography (RP HPLC). This method can help separate retatrutide from related compounds, impurities, and degradation products based on differences in their interactions with the stationary and mobile phases.
The resulting chromatographic data can then be used to evaluate chromatographic purity and, when the method has been properly developed and validated using an appropriate reference standard, to determine the retatrutide content. In addition to RP HPLC, liquid chromatography mass spectrometry (LC MS) or liquid chromatography high resolution mass spectrometry (LC HRMS) can be used to help confirm the identity of retatrutide.
Mass spectrometry provides information about molecular mass, complementing the data obtained from chromatography. This is important because retention time in HPLC alone may not always be sufficient to definitively confirm the identity of a peptide.
LC MS or LC HRMS can also provide information about related compounds, degradation products, and other molecular characteristics that may be present in the sample.
Support Drug Candidate Research Through Laboratory Testing
The development of drug candidates such as retatrutide requires reliable scientific data to understand the characteristics and quality of the compounds being investigated. Support your research and development process with appropriate laboratory testing.
Contact IML Testing & Research today and discuss your Chemical Compound Testing or other research testing requirements with our team!
Author: Elmira
Editor: Lina
Daftar Pustaka
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Ganamurali, N., et al. (2026). The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development, 15(1), e70001. https://doi.org/10.1002/cpdd.70001
Eli Lilly and Company. (2026). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1). ClinicalTrials.gov Identifier: NCT05929066. https://clinicaltrials.gov/ct2/show/NCT05929066
